AstraZeneca plc (LON:AZN) has been assigned a GBX 3,900 ($50.63) price objective by Goldman Sachs Group, Inc. (The) in a research report issued to clients and investors on Friday. The firm currently has a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group, Inc. (The)’s price target indicates a potential downside of 12.30% from the stock’s current price.
AZN has been the topic of a number of other reports. Barclays PLC reiterated an “overweight” rating and set a GBX 6,000 ($77.89) price target on shares of AstraZeneca plc in a research report on Friday, April 28th. Liberum Capital reiterated a “buy” rating and set a GBX 5,100 ($66.21) price target on shares of AstraZeneca plc in a research report on Thursday, April 27th. UBS AG set a GBX 5,150 ($66.86) price target on shares of AstraZeneca plc and gave the company a “neutral” rating in a research report on Tuesday, June 27th. HSBC Holdings plc set a GBX 4,500 ($58.42) price target on shares of AstraZeneca plc and gave the company a “sell” rating in a research report on Tuesday, June 6th. Finally, Citigroup Inc. reiterated a “buy” rating and set a GBX 6,000 ($77.89) price target on shares of AstraZeneca plc in a research report on Friday, July 28th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the stock. AstraZeneca plc currently has an average rating of “Hold” and a consensus price target of GBX 4,932.67 ($64.04).
Shares of AstraZeneca plc (AZN) opened at 4447.00 on Friday. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The firm’s market capitalization is GBX 56.30 billion. The company’s 50-day moving average is GBX 4,818.59 and its 200 day moving average is GBX 4,863.31.
In other news, insider Nazneen Rahman acquired 39 shares of the stock in a transaction on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.73) per share, with a total value of £1,704.30 ($2,212.51).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.
